PXMDPaxMedica, Inc.

About PaxMedica, Inc. (PXMD)

PaxMedica, Inc. (PXMD) is a Biotechnology company headquartered in Boston, MA, United States whose shares trade over-the-counter on the Expert Market tier.

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin for neurologic indications; and HAT-301 for the treatment of stage 1 East African HAT. The company has a research collaboration with PoloMar Health to investigate the use of emodin in a clinical program as a potential treatment for patients with autism spectrum disorder.

PXMD key facts

Ticker symbol

PXMD

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

Boston, MA, United States

Country of incorporation

US

Estimated market cap

$12.6K (as of Apr 16, 2025)

Shares outstanding

126,066,870

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Latest filing

8K Report (Jul 16, 2024)

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with P